Know Cancer

or
forgot password

A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma


Phase 2
18 Years
N/A
Not Enrolling
Both
Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)

Thank you

Trial Information

A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma


Inclusion Criteria:



- Pathologically proven high-grade glioma (WHO III or IV) with astrocytic component and
must be in recurrence after treatment with bevacizumab

- Patients must have received conventional radiation therapy of total radiation dosage
(ranging from 5400 to 6000 cGy administered in daily fractions of 150 to 200 cGy over
6 weeks) with concurrent temozolomide.

Patients must have received bevacizumab and be in recurrence after bevacizumab treatment.

- Patients must be at least 28 days from last administration of cytotoxic chemotherapy
and at least 14 days from the last administration of bevacizumab.

- Patients must be >18 years of age.

- Patients must have a life expectancy > 6 weeks

- Patients must have a Karnofsky Performance Score (KPS) >=50

- If female, patients of childbearing potential must have a negative serum
beta-hCG pregnancy test and must agree to use hormonal or barrier birth control
with spermicidal gel to avoid pregnancy during the study

- Adequate organ function (obtained within 14 days prior to randomization and
analyzed by the central laboratory) as evidenced by:

1. Absolute neutrophil count (ANC) >=1.5 X 10^9/L without myeloid growth
factor support for 7 days preceding the lab assessment;

2. Hemoglobin (Hgb) >= 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if
hemoglobin is corrected to >= 9 g/dL (90 g/L) as by growth factor or
transfusion prior to randomization;

3. Platelet count >=100 X 10^9/L without blood transfusions for 7 days
preceding the lab assessment;

4. Bilirubin <= 1.5 X upper limit of normal (ULN), except for patients with
documented history of Gilbert's disease;

5. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 2.5
X ULN

6. Alkaline phosphatase (AP) <= 3 X ULN

7. Serum creatinine <= 1.5 mg/dL (133 ┬Ámol/L) or calculated creatinine
clearance >= 50 mL/min (using Cockcroft-Gault formula);

8. Women of childbearing potential (WCBP): negative serum pregnancy test (this
test is required of all women unless post-menopausal, defined as 12
consecutive months since last regular menses, or surgically sterile).

- Patients must be willing and able to comply with the protocol and provide
written informed consent prior to study-specific screening procedures.

Exclusion Criteria:

Patients who meet any of the following criteria must not be permitted entry to the study.

- Patients who have had chemotherapy within 28 days, radiotherapy within 28 days,
biological therapy within 14 days, and investigational therapy within 21 days prior
to first dose of experimental drug.

- Patients who have received prior treatment for cancer with a camptothecin derivative
(eg, irinotecan, topotecan, and investigational agents including but not limited to
exatecan, rubitecan, gimatecan, karenitecan, SN38 investigational agents, EZN-2208,
SN-2310, and AR-67).

- Patients with the following co-morbid disease or incurrent illness:

1. Patients with chronic or acute GI disorders resulting in diarrhea of any
severity grade; patients who are using chronic anti-diarrheal supportive care
(more than 3 days/week) to control diarrhea in the 28 days prior to first dose
of investigational drug.

2. Patients with known cirrhosis diagnosed with Child-Pugh Class A or higher liver
disease.

3. Prior malignancy except for non-melanoma skin cancer and carcinoma in situ (of
the cervix or bladder), unless diagnosed and definitively treated more than 3
years prior to first dose of investigational drug.

4. Severe/uncontrolled inter-current illness within the previous 28 days prior to
first dose of investigational drug.

5. Significant known cardiovascular impairment (NYHA CHF > grade 2, unstable
angina, myocardial infarction within the previous 6 months prior to first dose
of investigational drug, or existing serious cardiac arrhythmia).

6. Patients who require daily use of oxygen supplementation in the 28 days prior to
first dose of investigational drug.

7. Any other significant co-morbid conditions that in the opinion of the
Investigator would impair study participation or cooperation.

- Patients with a known allergy or hypersensitivity to any of the components of the
investigational therapy, including PEG or topoisomerase inhibitors.

- Patients receiving the following medications at the time of first dose of
investigational drug:

- Pharmacotherapy for hepatitis B or C, tuberculosis, or HIV.

- enzyme inducing anti-epileptic medications (EIAEDs)

- other chemotherapy, other investigational agents , or biologic agents for

- the treatment of cancer including antibodies(eg, bevacizumab,

- trastuzumab, or pertuzumab) or any investigational agent(s).

- Pregnant or nursing patients will be excluded from the study.

- Patients receiving active treatment for HIV will be excluded from this study because
non-nucleoside reverse transcriptase inhibitors, protease inhibitors and maraviroc (a
CCR5-antagonist) are extensively metabolized by the cytochrome P450 system.
Interactions with these drugs may induce or inhibit irinotecan or SN38 metabolism,
leading to over or under-dosing.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival, assessed by Revised Assessment in Neuro-oncology (RANO) criteria

Outcome Description:

Will be described using Kaplan-Meier estimates. The PFS probability at 6 weeks (PFS-6week) will be estimated with an 80% power and 95% confidence intervals (80% in accord with the planned alpha level, 95% for comparability with other studies, confidence intervals based on the Greenwood formula for the variance of a survival probability).

Outcome Time Frame:

6 weeks from first administration of NKTR-102

Safety Issue:

No

Principal Investigator

Lawrence Recht, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Food and Drug Administration

Study ID:

BRN0021

NCT ID:

NCT01663012

Start Date:

July 2012

Completion Date:

May 2013

Related Keywords:

  • Anaplastic Astrocytomas
  • Anaplastic Oligodendrogliomas
  • Glioblastomas (GBM)
  • Astrocytoma
  • Glioblastoma
  • Oligodendroglioma

Name

Location

Stanford University School of Medicine Stanford, California  94305-5317